Proscia earns top score in KLAS digital pathology report
April 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Leica Biosystems launches Aperio GT Elite scanner
April 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
Thermo Fisher introduces LDT for tacrolimus dosing
April 2026—Thermo Fisher Scientific launched the TacroType pharmacogenetic test, a laboratory-developed test designed to help inform clinicians on dosing tacrolimus, an immunosuppressive drug for transplant recipients.
Siemens launches RUO blood-based tau assays
April 2026—Siemens Healthineers has launched the Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived Tau assays for research use.
Illumina launches TruPath Genome
April 2026—Illumina has launched TruPath Genome, which provides high-quality, comprehensive whole genome insights for genetic disease. It features a hands-on time of about 10 minutes and generates 16 whole genomes per day.
HelioLiver test available to Quest providers
April 2026—Helio Genomics’ blood-based HelioLiver test is now available to physicians and patients through Quest Diagnostics.
ARUP creates innovation central laboratory
March 2026—ARUP Laboratories has launched an innovation central laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Henry Schein, CytoChip enter distribution agreement
March 2026—Henry Schein entered into an exclusive distribution agreement with CytoChip for CitoCBC, a 510(k)-cleared, CLIA-waived, cartridge-based CBC system. CitoCBC uses blood collected in a venous draw tube to analyze 16 parameters, including the five-part differential. Test results are available in eight minutes.
BD launches urine collection system
March 2026—BD launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system that expands testing capabilities from a single urine specimen.
Guardant360 CDx approved for use with encorafenib
March 2026—The Food and Drug Administration has approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with encorafenib (Braftovi, Pfizer) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.